export default function AfamelanotideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Afamelanotide (Scenesse) is a prescription drug that causes the skin to tan by stimulating melanin production — and it&rsquo;s FDA-approved to protect people with a rare genetic condition that makes sunlight physically painful. In the broader community, it&rsquo;s sought after as a medical-grade tanning compound. The distinction between those two uses matters: one has a clinical justification, the other doesn&rsquo;t.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Tanning-Curious Person — Interested in a deeper, longer-lasting tan without sun damage</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want a real tan without burning. I&rsquo;ve seen Melanotan discussed online but also this Scenesse thing that&rsquo;s an actual approved drug. Is this safer than the peptide stuff people inject themselves?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It produces real, deep tanning with minimal UV exposure</strong><br />Afamelanotide stimulates the skin to produce more melanin — the pigment that gives skin its color and absorbs UV light. The result is a significant tan that develops even with limited sun exposure. For someone who burns easily or wants color without time in the sun, that&rsquo;s an obvious appeal.</li>
          <li><strong>It&rsquo;s an approved pharmaceutical, not an underground compound</strong><br />Unlike Melanotan-II, which is sourced from research chemical suppliers with no quality oversight, afamelanotide is a real drug with real manufacturing standards, peer-reviewed clinical trials, and regulatory approval. For someone aware of the risks of unregulated peptides, the existence of a pharmaceutical version feels like a safer path.</li>
          <li><strong>Long-lasting effect from a single implant</strong><br />Afamelanotide is delivered as a small implant inserted under the skin that slowly releases the compound over two months. The sustained delivery means the effect isn&rsquo;t dependent on remembering daily injections — and the gradual release avoids the peaks and side effects of rapid dosing.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Afamelanotide is approved for erythropoietic protoporphyria — a serious genetic disease that causes burning pain from sun exposure. Its approval is for a medical need, not aesthetic tanning. For healthy people seeking a tan, the risk-benefit calculation is completely different: you get cosmetic benefit but take on the full risk profile, including the theoretical concern about melanin stimulation and melanoma monitoring that exists for all melanocortin agonists. The drug is also not practically accessible for aesthetic use — it requires a provider, is expensive, and is prescribed for EPP, not tanning goals. The community-accessible version, Melanotan-II, has its own risks and is a different compound entirely. Net: afamelanotide is a legitimate drug solving a real medical problem; it is not a tanning shortcut that can simply be obtained for aesthetic use, and the melanoma monitoring concern means it should not be dismissed as purely cosmetic.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Sun-Conscious Person — Interested in photoprotection and skin health</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have fair skin, I burn constantly, and I hate the idea of cumulative sun damage. If something could make my skin actually produce more protective pigment, is that a meaningful intervention or just cosmetic?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Melanin is the skin&rsquo;s actual UV defense system</strong><br />Sunscreen is external photoprotection. Melanin is the internal one — it&rsquo;s produced in skin cells and absorbs UV radiation before it can damage DNA. People with naturally low melanin production (fair skin types) have genuinely reduced photoprotection. The idea of increasing melanin production as a real physiological UV defense — not just blocking sun at the surface — is conceptually appealing.</li>
          <li><strong>Clinical evidence for protection in EPP patients is solid</strong><br />In the Phase III trials for EPP, afamelanotide significantly increased the amount of time patients could spend outdoors without pain. That is a measurable, real protection outcome — not just a cosmetic color change. The UV protection associated with increased melanin is physiologically real.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The protection established in EPP trials applies to people with a specific disease whose baseline melanin production is severely impaired. There is no clinical evidence that boosting melanin in someone with normal-range skin provides meaningful additional UV protection in practice — especially compared to high-SPF sunscreen applied consistently. Additionally, stimulating melanocytes raises the question of whether it could promote existing abnormal cells — which is why EPP patients on afamelanotide receive regular dermatological monitoring for melanocytic lesions. For a healthy person seeking photoprotection, consistent daily sunscreen is both proven and risk-free. Net: the biology is real and interesting, but applying EPP trial outcomes to healthy sun-protective goals stretches the evidence well past what it actually shows.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Research-Forward Biohacker — Interested in melanocortin biology and the relationship between pigmentation and systemic effects</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I understand afamelanotide is more melanocortin-receptor-selective than Melanotan-II. I&rsquo;m interested in whether the tissue-specific actions of different melanocortin agonists have been characterized well enough to understand the risk differential between them.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Afamelanotide is more receptor-selective than community alternatives</strong><br />Melanotan-II is a broad-acting melanocortin agonist that hits multiple receptor subtypes — which is why it produces sexual side effects and appetite suppression alongside tanning. Afamelanotide has greater selectivity for the receptor subtype responsible for pigmentation, with less activity at the subtypes responsible for those other effects. That receptor profile difference is pharmacologically meaningful and represents a more targeted intervention.</li>
          <li><strong>The sustained-release implant is a superior delivery model</strong><br />From a pharmacokinetics standpoint, the implant format avoids the peaks and troughs of subcutaneous injection and provides stable systemic concentrations. For someone interested in optimizing dosing curves, this is the more sophisticated delivery method. The clinical trials were also conducted with proper controls — providing a real efficacy and safety reference point that community compounds lack entirely.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Even the more selective receptor profile doesn&rsquo;t eliminate the monitoring requirement. Afamelanotide&rsquo;s prescribing information requires regular skin checks for melanocytic lesion development — that concern is not eliminated by receptor selectivity, it is inherent to stimulating melanocyte activity. The clinical development of afamelanotide was specifically designed around EPP&rsquo;s extreme, measurable medical need — the risk-benefit calculation that justified approval does not automatically extend to aesthetic or longevity applications. The evidence base for systemic melanocortin effects beyond pigmentation (inflammatory modulation, metabolic effects) in the afamelanotide context is limited and not the basis of its approval. Net: more sophisticated than Melanotan-II from a pharmacology standpoint, but still carries monitoring requirements, is approved only for a specific medical indication, and the interesting mechanistic territory around systemic melanocortin signaling remains mostly unexplored in controlled human research.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Afamelanotide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a general-population tanning drug — approved only for a specific rare disease</li>
              <li>Not interchangeable with Melanotan-I or Melanotan-II — different compound, different receptor profile, different formulation</li>
              <li>Not risk-free even as a pharmaceutical — requires regular dermatological monitoring</li>
              <li>Not available through normal prescription channels for aesthetic use</li>
              <li>Not equivalent to subcutaneous injection — administered as a biodegradable implant by a provider</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The only approved melanocortin agonist drug — genuinely solves a medically serious problem for EPP patients</li>
              <li>More receptor-selective than community melanocortin compounds, with a cleaner side effect profile</li>
              <li>Sustained-release implant delivery is a pharmacokinetically superior format compared to injection</li>
              <li>Phase III trial data is real and shows meaningful protection outcomes for EPP patients</li>
              <li>Illustrates how receptor selectivity within a peptide family can meaningfully change the therapeutic and side-effect profile</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
